Growing budgetary pressure is a central theme in France as it prepares for the publication of the government's 2026 Social Security Finance Bill (PLFSS).

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

The UK and India’s new £4.8bn free trade agreement (FTA) is expected to allow new opportunities for Indian medical device and pharmaceutical manufacturers.

Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.

In today’s tech-driven landscape, it seems like every software solution in the clinical industry needs to have some AI ...

The clinical trial industry has long recognized the importance of standardization in driving efficiency and ensuring data quality. Efforts ...

Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.